07.11.

2024

To,

BSE Limited National Stock Exchange of India Limited

Phiroze JeeJeebhoy Towers, Exchange Plaza, Plot no. C/1,
Dalal Street, G Block, Bandra-Kurla Complex
Fort, Mumbai – 400 001 Bandra (E), Mumbai - 400 051
Scrip Code: 543318 Trading Symbol: CLEAN

Subject: Investor Presentation.

Dear Sir/Madam,

In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, Financial Results presentation for the Quarter and half year ended
30th September, 2024 is enclosed.

The aforesaid presentation is also available on the Company’s website.

You are requested to take the same on record.

Thanking You.
For Clean Science and Technology Limited

Ruchi Digitally signed

by Ruchita Vij
Date:

ta Vij 2024.11.07
13:09:43 +05'30'

Ruchita Vij
Company Secretary

Encl: As above
Clean Science and
Technology Ltd.
Investor Presentation

Q2 FY 2025 I NOVEMBER 2024

SAFE HARBOUR

This investor presentation has been prepared by Clean Science and Technology Limited (“CSTL”) and does not constitute
a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other
documentation or information (or any part thereof) delivered or supplied, should not be deemed to constitute an offer.
No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness,
accuracy, completeness or correctness of such information or opinions contained herein. The information contained in
this presentation is only current as of its date. Certain statements made in this presentation may not be based on
historical information or facts and may be “forward-looking statements”, including those relating to the general business
plans and strategy of Clean Science and Technology , its future financial condition and growth prospects, future
developments in its industry and its competitive and regulatory environment, and statements which contain words or
phrases such as ‘will’, ‘expected to’, ‘horizons of growth’, ‘strong growth prospects’, among many others, or similar
expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties
and other factors that could cause actual results, opportunities and growth potential to differ materially from those
suggested by the forward-looking statements.
Clean Science and Technology Limited may alter, modify, or otherwise change in any manner, the content of this
presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and
disseminated in any manner.

2
Q2 FY 2025 & H1 FY2025
Update
Q2 FY2025 UPDATE
Volume led y-o-y growth in revenue; EBITDA margins continue to be strong

Revenue in INR Crore

237 217 188 181 195 225 217 228

Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25

49.1%
46.1% 44.9% 44.4% 45.5%
41.3% 42.4% 42.1%

39.2%
33.1% 33.6% 34.4% 34.1% 36.6%
34.7%
29.9%

8.7% 8.4% 9.5% 9.0% 7.9% 8.7% 9.6%

6.7%

Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25

Note: RM - raw material; P&F – power & fuel

P&F costs % RM costs % EBITDA %

➢ Incurred total capex of ~ Rs. 155 crores during H1 FY2025 primarily towards investment in Clean Fino Chem Ltd. (CFCL), wholly owned subsidiary of CSTL
CAPEX &
➢ Secured Responsible Care certification for 3 years
BUSINESS UPDATE
➢ Plans on track to commercialize pharma intermediate during Q3 FY2025
4
Q2 FY2025 P&L OVERVIEW - STANDALONE
Growth momentum continues on annual basis; steady profitability on sequential basis

P&L (INR Crore) Q2 FY2025 Q1 FY2025 Q-o-Q (%) Q2 FY2024 Y-o-Y (%)

Sale of products 224.8 214.7 5% 178.1 26%

Other operating income 3.3 2.7 3.0

Total Revenue 228.1 217.3 4% 181.1 26%

Raw material expenses 82.3 73.2 13% 61.8 33%

Raw material % 36.6% 34.1% 34.7%

Other operating expenses 51.1 46.5 10% 43.7 17%

EBITDA 94.6 97.6 (3)% 75.4 25%

EBITDA % 42.1% 45.5% 42.4%

Depreciation expenses 11.2 11.1 1% 11.0 2%

Finance costs 0 0.0 0.2

Other Income 10.4 9.6 8% 5.1 104%

Profit before tax (PBT) 93.7 96.2 (3)% 69.4 35%

PBT % 41.7% 44.8% 39.0%

Profit after tax (PAT) 67.4 72.1 (7)% 51.9 30%

PAT% 30.0% 33.6% 29.1% 5

H1 FY2025 FINANCIAL OVERVIEW - STANDALONE
Strong growth in profitability; healthy cash balance

As at As at
P&L (INR Crore) H1 FY 2025 H1 FY 2024 Y-o-Y (%) Balance Sheet (INR Crore)
30-Sept.-2024 31-March-2024
Assets
Sale of products 439.5 363.3 21%
Non-current assets
Fixed Assets 378.1 396.6
Other operating income 5.9 5.9
Capital work-in-progress 2.6 1.8
Total Revenue 445.4 369.2 21% Right of use asset 3.8 3.8
Other non-current assets 526.8 377.5
Raw material expenses 155.4 134.4 16% Total non-current assets 911.3 779.7
Current assets
Raw material % 35.4% 37.0% Inventories 122.3 110.5
Investments 267.0 292.5
Other operating expenses 97.6 82.7 18% Trade receivables 179.6 161.8
Cash and bank balances 10.0 9.0
EBITDA 192.4 152.1 26% Other current assets 10.7 16.9
Total current assets 589.6 590.8
EBITDA % 43.8% 41.9% Total assets 1,500.8 1,370.5
Depreciation expenses 22.3 21.6 3% Equity and Liabilities
Net-worth 1,324.7 1,215.5
Finance costs 0.1 0.2 Non-current liabilities
Borrowings - -
Other Income 20.0 17.4 15% Provisions 0.9 0.6
Other non-current liabilities 38.1 33.7
Profit before tax (PBT) 190.0 147.7 29%
Total non-current liabilities 39.0 34.3
PBT % 43.2% 40.6% Current liabilities
Trade payables 96.7 93.7
Profit after tax (PAT) 139.6 110.5 26% Other current liabilities 40.5 27.0
Total current liabilities 176.1 120.7
PAT% 31.8% 30.4% Total equity and liabilities 1,500.8 1,370.5

6
H1 FY2025 - REVENUE PROFILE
Performance segment witnessed strong growth; product mix and geography mix continue to diversify

REVENUE MIX BY SEGMENT REVENUE MIX BY GEOGRAPHY

14% 14% 10%

10%

19% 22% 34% 20% 36%

18% H1 FY25 H1 FY24 H1 FY25 H1 FY24
69% 67%
15%
16% 18% 19%

Performance Pharma & Agro FMCG China India Europe Americas Row
chemicals Intermediates chemicals

➢ Performance segment witnessed strong growth amongst all segments, ➢ China witnessed higher growth amongst all geographies, followed by
led by increased volumes Europe during H1

➢ Pharma and FMCG segment witnessed similar growth which was volume ➢ For Q2 FY2025, Americas witnessed higher growth on sequential and
led y-o-y basis

➢ HALS’ sales volume and product mix improving ➢ Domestic market share is steady

7
H1 FY2025 FINANCIAL OVERVIEW - CONSOLIDATED
Profitability to increase as the CFCL operations scale up

As at As at
P&L (INR Crore) H1 FY 2025 H1 FY 2024 Y-o-Y (%) In INR Crore
30-Sept.-2024 31-March-2024
Assets
Sale of products 456.1 363.3 26%
Non-current assets
Other operating income 6.1 5.9 Fixed Assets 649.8 598.7
Capital work-in-progress 30.0 57.3
Total Revenue 462.1 369.2 25% Right of use asset 36.3 36.6
Other non-current assets 50.5 46.3
Raw material expenses 167.0 134.4 24% Total non-current assets 766.6 739.0
Current assets
Raw material % 36.6% 37.0% Inventories 147.6 123.7
Investments 322.8 302.4
Other operating expenses 110.8 83.9 32% Trade receivables 190.1 163.7
Cash and bank balances 11.4 10.4
EBITDA 184.3 150.9 22% Other current assets 62.3 59.5
Total current assets 734.2 659.7
EBITDA % 40.4% 41.5% Total assets 1,500.8 1,398.7
Equity and Liabilities
Depreciation expenses 33.3 21.9 52%
Net-worth 1,297.3 1,203.2
Finance costs 0.2 0.3 Non-current liabilities
Borrowings - -
Other Income 21.0 19.4 8% Provisions 1.1 0.8
Other non-current liabilities 39.1 34.6
Profit before tax (PBT) 171.9 148.1 16% Total non-current liabilities 40.1 35.5
Current liabilities
PBT % 37.7% 40.8% Trade payables 107.7 108.5
Other current liabilities 55.7 51.6
Profit after tax (PAT) 124.6 111.1 12% Total current liabilities 163.4 160.0
Total equity and liabilities 1,500.8 1,398.7
PAT% 27.3% 30.6%

8
Corporate presentation
CLEAN SCIENCE AND TECHNOLOGY AT A GLANCE
A brief Introduction about the Company

➢ One of the fastest growing and among the most profitable fine and specialty chemical companies globally. Among the largest
manufacturers of certain specialty chemicals developed in-house.

➢ Among the few global organizations focused on developing ingenious technologies with unique, innovative, sustainable, and cost-
effective catalytic manufacturing processes

500+ Global 1,100+ Strong team 16+ Accreditation &

and domestic customers across Zero Debt Company
(9% women) Certifications
35+ countries

Sustainability and 4 manufacturing units with 90+ Scientists over

64% revenues from exports
ESG deeply ingrained in our State-of-art Pilot facility 4 R&D facilities
philosophy

10
 COMPANY EVOLUTION
Continuous R&D and Innovation has led to new product launches on a consistent basis

YEAR 2009 2011 2014 2018 2020 2021 2022 2023 2024

REVENUES (INR Crore) 1 19 120 241 419 512 685 936 789
➢ Commercialized
largest plant for
➢ Commercialized plant HALS from India
to manufacture P-BQ 2022 2023
and TBHQ
➢ Commercialized unique ➢ Commercialized 2024
vapour phase route to 2020 ➢ Expanded
plant to
manufacture Anisole 2021 capacity of
MEHQ, Guaiacol manufacture
➢ Backward integration HALS 770 & 701
and BHA by 50%
for flagship products
➢ Technocrat Promoters ➢ Commercialized
collaborated to develop unique
novel, clean and sustainable ➢ Commercialized technology to
chemical processes unique catalytic manufacture
➢ Aligned to the philosophy, technology to 2018 DCC
Company was named as manufacture 4-MAP
2014
Clean Science and
Technology
2009
➢ Commercialized unique
2011 catalytic forward
integration to
2006 ➢ Commercialized unique manufacture BHA
catalytic technology to
manufacture MEHQ
and Guaiacol

11
DIVERSIFIED PRODUCT PROFILE SERVING CRITICAL END-USER INDUSTRIES
Largest capacity in the world for our flagship products

PERFORMANCE PHARMA AND AGRO FMCG

CHEMICALS INTERMEDIATES CHEMICALS

MEHQ (Monomethyl Ether of Hydroquinone) Guaiacol

4-MAP (4-Methoxy Acetophenone)
➢ Used as polymerization inhibitor in acrylic acids, acrylic esters, super ➢ Pre-cursor to manufacture APIs for cough
absorbent polymers (diapers and sanitary pads) syrup (pharma industry) ➢ Used in UV blocker in sunscreens
➢ Pre-cursor for agrochemical industry ➢ Key raw material to produce Vanillin (cosmetics industry)

1 in World & India

BHA (Butylated Hydroxy Anisole) 2 in World 1 in India

1 in World & India
➢ Used as anti-oxidant in food and feed industry DCC (Dicyclohexyl Carbodiimide)
1 in World & India
➢ Used as reagent in anti-retroviral
AP (Ascorbyl Palmitate)
➢ Used in infant food formulations, breakfast cereals and cosmetics 2 in World 1 in India
Anisole
1 in World & India
Veratrole ➢ Precursor to perfumes, insect
TBHQ (Tertiary Butyl Hydroquinone) pheromones, pharmaceuticals
➢ Intermediate in agrochemical industry
➢ Stabilizer in oil industry ➢ Majority of Anisole produced is used for
captive consumption
2 in World & India Amongst largest in India

HALS (Hindered Amine light Stabilizers) p-BQ (Para Benzoquinone)

➢ HALS 701 is used in water treatment 1 in World & India
➢ HALS 770, 622, 944, 119, 783 is used for UV stabilization in a variety of polymers
➢ Intermediate in agrochemical industry

1 in India
2 in World 1 in India
12
KEY DIFFERENTIATORS THAT ADD VALUE
Unique benefits that set our business apart from competition

INNOVATION GLOBAL LEADERS PREFERRED PARTNER STATE-OF-THE-ART

Strategic process innovation Among the largest OF CHOICE Multiple, automated
and new product producers globally of Strong and long term manufacturing facilities with
development driven by a critical specialty chemicals relationships with a well zero liquid discharge and strong
strong with diversified diversified marquee customer focus on EHS
in-house R&D team applications base

PROMOTERS FORMULATION STATISTIC

Technocrat promoters Unique, innovative, Strong and
supported by an sustainable and cost- consistent
experienced workforce effective catalytic financial
with extensive domain manufacturing process performance
knowledge

13
STEADFAST FOCUS ON RESEARCH & DEVELOPMENT
Pioneered commercialization of catalytic reactions

Research and Development team’s focus areas

Enhance our existing catalyst Develop products with high demand

Expand product portfolio in the
1 systems to further optimize yield 2 performance chemical segment 3 which are produced by limited
and selectivity manufacturers globally

BACKED BY DIVERSE LED BY EXEMPLARY

COMPETENCY ACROSS
TECHNOLOGY R&D TEAM
~10+ CHEMISTRIES

Continuous flow reaction March 2018 March 2024

Hydroxylation Hydrogenation

Grignard Reaction Chlorination 1 PhD 9 PhDs

Vapour phase reaction
Oxidation Polymeric Reaction 22 scientists 90 scientists
Tri-phasic reaction
Alkylation Esterification
4 independent R&D
Fixed bed reaction labs with pilot facility
Catalysis Halogenation

14
COHESIVE AND TECHNOCRAT PROMOTERS
Strong visibility on longevity of Promoters’ engagement in the business

Over 28 years of work experience in Over 18 years of experience in the

the chemical industry. chemical industry.

Industry experience of over 5 decades Bachelor of Chemical Technology –

Institute of Chemical Technology,
Mumbai, India (formerly known as
Bachelor of Chemical Engineering – UDCT)
Institute of Chemical Technology,
ASHOK BOOB Mumbai, India (formerly known as SIDDHARTH SIKCHI Master of Science in Organic
Managing Director Executive Director Chemistry – University of Manitoba,
UDCT)
Key functions: Projects, Key functions: Canada.
Manufacturing Capabilities Marketing, R&D

Over 23 years of expertise in the

chemical industry. Over 9 years of work experience in
the chemical industry.
Industry experience of over 5 decades
Bachelor of Chemical Engineering –
Pune University, India

KRISHNA BOOB Bachelor of Pharmacy – University of PARTH MAHESHWARI

Mumbai, India MBA – Babson College, USA
Executive Director Executive Director
Key functions: Public Key functions:
relations, Purchase Business operations

Promoters’ sole business interest remains Clean Science and Technology with 75% stake
15
ROBUST CORPORATE GOVERNANCE
Distinguished Board of Directors and reputed financial market participants underscore sound governance

PROFILE OF NON-EXECUTIVE, INDEPENDENT DIRECTORS ON THE BOARD

PRADEEP RATHI PROF. G. D. YADAV Sanjay Kothari

Chairman and Non-Executive Director Non-Executive, Independent Director Non-Executive, Non-Independent Director
B.Sc, M.S. (MIT, USA)
MBA (Columbia, USA)
B.Chem. Engineering, B.Com (University of Calcutta)
Ph.D Technology Member of ICAI and ICSI
Chairman – Sudarshan Chemicals

KEVAL DOSHI MADHU DUBHASHI

Non-Executive, Independent Director Non-Executive, Independent Director
B.Com. (University of Mumbai)
Member of ICAI
PG in Business Administration
Erstwhile Partner at Ernst & Young LLP (IIM Ahmedabad)

Balanced board ensures transparency and accountability

Highly experienced and

Mr. Pradeep Rathi, Prof. G. D. More than 1/3rd Board
diversified non-executive
Yadav, and Mr. Sanjay Kothari members are independent Separate Chairman &
directors, are also board
have been Board members for Non-executive directors form Managing Director
members of other reputed
over a decade majority of all committees
listed companies

16
CONTINUED COMMITMENT TOWARDS SUSTAINABILITY AND ESG
Sustainability and ESG initiatives are embedded in our long term growth strategy

ENVIRONMENT EMPATHY (E) SOCIAL RESPONSIBILITY (S) CORPORATE GOVERNANCE (G)

➢ Utilize resources efficiently, reduce waste ➢ Total contribution towards CSR activities ➢ Big 4 Statutory auditors
and minimize emissions as part of our during last 3 years is INR 16 crores
sustainability commitment ➢ Highly experienced, competent and balanced
➢ Health, safety and wellbeing of Board driving corporate ethics and values
➢ We aim to plant more than 50,000 trees over employees is integral part of all our
the next five years activities ➢ Long term & short term ratings by CRISIL are
AA- (Stable) and A1+ respectively
➢ 19.4 MW of solar capacity. Share of ➢ Continual improvement in safety
renewable energy in power consumption at measures have resulted in zero ➢ Dividend track record with defined dividend
65%. casualties till date payout policy

➢ Reduced GHG emission by 3.5% y-o-y ➢ Our key initiatives include regular safety ➢ Received Maharashtra State Export award
audits, safety trainings and health for 4 consecutive years
➢ Reduced water consumption by 2.3% y-o-y
checkups among others ➢ No auditor qualification or re-statements of
➢ Reduced energy consumption by 1.3% y-o-y financial statements till date

FOCUS ON SUSTAINABILITY FOCUS ON CSR ACTIVITIES FOCUS ON GOVERNANCE

GreenCo Together for Ecovadis

Certificate Sustainability Audit Nomination And Stakeholders
Vocational Environment Medical Committee Remuneration Relationship
Skills Sustainability Relief Committee Committee

Risk Management Corporate Social

Reduce Recycle Reuse Healthcare Education Committee Responsibility Committee

17
ADVANCED MANUFACTURING FACILITIES DESIGNED BY IN-HOUSE ENGINEERING TEAM
3 independent functional units under CSTL at Kurkumbh Industrial Area, Maharashtra with dedicated lines for each product

UNIT 1
NO plant closure notice
received from pollution
7 plants control board
Total area – 30,000 sq.m

All Units are ISO 9001,

ISO 14001 and ISO 45001
certified
UNIT 2

4 plants
Total area – 23,337 sq.m
Sustainable processes
ensures zero liquid
discharge (ZLD) facility

UNIT 3 ➢ Multiple dedicated plants for key products. To that extent, each plant is immune to
challenges in other plants
5 plants ➢ Independent plants for catalysts
Total area – 40,343 sq.m
➢ Each unit has a separate R&D facility, warehouse, engineering and utility section

18
COMMERCIALIZED LARGEST FACILITY FOR HALS FROM INDIA
Largest facility of Clean Science Group housed in its wholly owned subsidiary, Clean Fino Chem Ltd. at Kurkumbh Industrial Area, Maharashtra

UNIT 4

Commercialized in March 2024

Total area – 1,32,700 sq.mtrs. (34 acres)
Cost advantage - Tax incentive
Sizeable benefits of integrated facility

19
STRONG FINANCIAL PERFORMANCE
Resilient performance demonstrated over business cycles maintaining a debt free balance sheet

REVENUE EBITDA & EBITDA% PAT & PAT%

CAGR of 17% EBITDA CAGR of 16% PAT CAGR of 15%

419 512 685 936 789 185 259 300 403 337 140 198 229 304 248

51% 39%
33% 33%
44% 32%
44% 43% 31%
43%

FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024

RoCE RoNW Net FA & Net FA turnover(x)

58.5% 73.9% 51.5% 49.7% 38.7% 40.8% 36.7% 29.7% 29.8% 20.4% 166 186 296 427 401

2.8x
2.5x
2.3x
2.2x
2.0x

FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024

Note: RoCE = EBIT (ex. Other income)/capital employed (Gross FA + Working Capital); RoNW = PAT as % of net worth
Net Fixed Asset Turnover = Revenue from Operations/Net Fixed Assets; Net Fixed Assets include Property, plant and equipment, Right-of-use asset & Intangible Assets
(Nos. in INR crore)
20
KEY GROWTH LEVERS
Strategic initiatives and investments aimed at long term sustainable growth

FOCUS ON ESG AND SIGNIFICANT

SUSTAINABILITY GREENFIELD CAPEX
Capitalise on our core philosophy Planned capex on track for
of clean and green chemistry to commercialising new series of
address opportunities arising from products
the shift in demand to sustainable
chemistry. OUR KEY
GROWTH
DRIVERS
STRENGTHEN IN INDIA ADD NEW
AND EXPAND GLOBALLY COMPETENCIES
Focus on import substitution Adding new chemistries and
opportunities in India and add new process technologies with
export customers across significant focus on high value
geographies products that limited
manufacturers produce globally

NEW PRODUCT DEVELOPMENT

Strategic investments towards developing products for new range of
speciality chemicals that find applications across diverse and fast
growing end user industries
21
 THANK YOU
For further information, please contact:
PRATIK BORA
Email: [email protected]

Clean Science and Technology Limited

Website: https://www.cleanscience.co.in/